van Saene H K, Stoutenbeek C P, Zandstra D F
Department of Medical Microbiology, University of Liverpool.
Drugs. 1988;35 Suppl 2:29-34. doi: 10.2165/00003495-198800352-00008.
Emergence of bacterial resistance to antimicrobial agents was studied during a period of 30 months of continuous use of parenteral cefotaxime combined with oral non-absorbable polymyxin E and tobramycin (selective decontamination) in a surgical intensive care unit (ICU). No increase in drug-resistance micro-organisms was found. Colonisation of the oropharyngeal cavity or intestine or both by strains resistant to polymyxin E occurred in 8% of patients (invariably Proteus and Morganella species). Tobramycin-resistant strains (Escherichia coli, Acinetobacter and Pseudomonas species) were found in 4% of patients. Intestinal colonisation with cefotaxime-resistant bacilli (e.g. Enterobacter, Pseudomonas and Acinetobacter species) occurred in 10% of patients, but in most patients these strains were eliminated by therapy with the topical antibiotics within one week. The control of emergence of resistance has major implications for the antibiotic policy in the ICU: firstly, the number of different antimicrobials used is sharply reduced since the switching of antibiotics to treat suprainfections is seldom necessary; secondly, it is possible to use a third generation cephalosporin such as cefotaxime for systemic prophylaxis, without risk of induction of resistance.
在一家外科重症监护病房(ICU)连续30个月使用肠外头孢噻肟联合口服不吸收的多粘菌素E和妥布霉素(选择性去污)期间,研究了细菌对抗菌药物耐药性的出现情况。未发现耐药微生物增加。8%的患者出现对多粘菌素E耐药菌株在口咽腔或肠道或两者的定植(均为变形杆菌属和摩根菌属)。4%的患者发现有对妥布霉素耐药的菌株(大肠杆菌、不动杆菌属和假单胞菌属)。10%的患者出现肠道被头孢噻肟耐药杆菌(如肠杆菌属、假单胞菌属和不动杆菌属)定植,但在大多数患者中,这些菌株在一周内通过局部抗生素治疗被清除。耐药性出现的控制对ICU的抗生素政策具有重要意义:首先,由于很少需要更换抗生素来治疗二重感染,使用的不同抗菌药物数量大幅减少;其次,可以使用第三代头孢菌素如头孢噻肟进行全身预防,而不会有诱导耐药性的风险。